Shenzhen Salubris Pharmaceuticals Co Ltd (002294) - Total Assets

Latest as of September 2025: CN¥10.98 Billion CNY ≈ $1.61 Billion USD

Based on the latest financial reports, Shenzhen Salubris Pharmaceuticals Co Ltd (002294) holds total assets worth CN¥10.98 Billion CNY (≈ $1.61 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 002294 net assets for net asset value and shareholders' equity analysis.

Shenzhen Salubris Pharmaceuticals Co Ltd - Total Assets Trend (2006–2024)

This chart illustrates how Shenzhen Salubris Pharmaceuticals Co Ltd's total assets have evolved over time, based on quarterly financial data.

Shenzhen Salubris Pharmaceuticals Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2024)

Shenzhen Salubris Pharmaceuticals Co Ltd's total assets of CN¥10.98 Billion consist of 38.5% current assets and 61.5% non-current assets.

Asset Category	Amount (CNY)	% of Total Assets
Cash & Equivalents	CN¥0.00	10.8%
Accounts Receivable	CN¥589.72 Million	5.6%
Inventory	CN¥506.76 Million	4.8%
Property, Plant & Equipment	CN¥0.00	0.0%
Intangible Assets	CN¥2.81 Billion	26.9%
Goodwill	CN¥10.91 Million	0.1%

Asset Composition Trend (2006–2024)

This chart illustrates how Shenzhen Salubris Pharmaceuticals Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Shenzhen Salubris Pharmaceuticals Co Ltd market capitalisation.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Shenzhen Salubris Pharmaceuticals Co Ltd's current assets represent 38.5% of total assets in 2024, a decrease from 71.9% in 2006.
Cash Position: Cash and equivalents constituted 10.8% of total assets in 2024, up from 4.2% in 2006.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 26.0% of total assets, an increase from 0.0% in 2006.
Asset Diversification: The largest asset category is intangible assets at 26.9% of total assets.

Shenzhen Salubris Pharmaceuticals Co Ltd Competitors by Total Assets

Key competitors of Shenzhen Salubris Pharmaceuticals Co Ltd based on total assets are shown below.

Company	Country	Total Assets
Changchun High & New Technology Industries Group Inc SHE:000661	China	CN¥31.46 Billion
Yuhan Corp. KO:000100	Korea	₩3.05 Trillion
Tasly Pharmaceutical Group Co Ltd SHG:600535	China	CN¥15.34 Billion
Zhejiang Hisun Pharmaceutical Co Ltd SHG:600267	China	CN¥15.32 Billion
Zhejiang Jiuzhou Pharm Co Ltd SHG:603456	China	CN¥10.96 Billion
Shanghai Yizhong Pharmaceutical Co Ltd SHG:688091	China	CN¥1.54 Billion
Jiangsu Kanion Pharmaceutical Co Ltd SHG:600557	China	CN¥6.74 Billion
Cronos Group Inc TO:CRON	Canada	CA$1.18 Billion

Shenzhen Salubris Pharmaceuticals Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	3.15	3.72	1.94
Quick Ratio	2.78	3.24	1.59
Cash Ratio	0.00	0.00	0.00
Working Capital	CN¥2.98 Billion	CN¥2.75 Billion	CN¥1.03 Billion

Shenzhen Salubris Pharmaceuticals Co Ltd - Advanced Valuation Insights

This section examines the relationship between Shenzhen Salubris Pharmaceuticals Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	6.45
Latest Market Cap to Assets Ratio	0.80
Asset Growth Rate (YoY)	11.4%
Total Assets	CN¥10.47 Billion
Market Capitalization	$8.37 Billion USD

Valuation Analysis

Below Book Valuation: The market values Shenzhen Salubris Pharmaceuticals Co Ltd's assets below their book value (0.80x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: Shenzhen Salubris Pharmaceuticals Co Ltd's assets grew by 11.4% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Shenzhen Salubris Pharmaceuticals Co Ltd (2006–2024)

The table below shows the annual total assets of Shenzhen Salubris Pharmaceuticals Co Ltd from 2006 to 2024.

Year	Total Assets	Change
2024-12-31	CN¥10.47 Billion ≈ $1.53 Billion	+11.38%
2023-12-31	CN¥9.40 Billion ≈ $1.38 Billion	-3.67%
2022-12-31	CN¥9.76 Billion ≈ $1.43 Billion	+5.53%
2021-12-31	CN¥9.24 Billion ≈ $1.35 Billion	+33.61%
2020-12-31	CN¥6.92 Billion ≈ $1.01 Billion	-10.54%
2019-12-31	CN¥7.73 Billion ≈ $1.13 Billion	-2.17%
2018-12-31	CN¥7.90 Billion ≈ $1.16 Billion	+15.16%
2017-12-31	CN¥6.86 Billion ≈ $1.00 Billion	+5.05%
2016-12-31	CN¥6.53 Billion ≈ $956.15 Million	+21.30%
2015-12-31	CN¥5.39 Billion ≈ $788.27 Million	+16.70%
2014-12-31	CN¥4.62 Billion ≈ $675.47 Million	+26.70%
2013-12-31	CN¥3.64 Billion ≈ $533.12 Million	+22.23%
2012-12-31	CN¥2.98 Billion ≈ $436.17 Million	+21.90%
2011-12-31	CN¥2.45 Billion ≈ $357.80 Million	+12.43%
2010-12-31	CN¥2.17 Billion ≈ $318.25 Million	+22.74%
2009-12-31	CN¥1.77 Billion ≈ $259.29 Million	+333.66%
2008-12-31	CN¥408.60 Million ≈ $59.79 Million	+59.65%
2007-12-31	CN¥255.94 Million ≈ $37.45 Million	+61.31%
2006-12-31	CN¥158.66 Million ≈ $23.22 Million	--

About Shenzhen Salubris Pharmaceuticals Co Ltd

SHE:002294 China Drug Manufacturers - Specialty & Generic

Market Cap

$8.37 Billion

CN¥57.18 Billion CNY

Market Cap Rank

#2542 Global

#322 in China

Share Price

CN¥51.29

Change (1 day)

-1.18%

52-Week Range

CN¥38.05 - CN¥68.30

All Time High

CN¥68.30